Fibrotic diseases of the heart and liver impact a significant portion of the global population and are a growing public health concern. Fibrosis occurs when fibroblasts deposit excess extracellular material within the tissue in response to certain stimuli or injury. Myocardial fibrosis is associated with nearly all forms of heart disease. The pathological changes that can result from fibrosis include cardiomyocyte hypertrophy, chamber dilation, heart valve stiffening, and others, all of which contribute to heart failure. Nonalcoholic steatohepatitis (NASH) is a fatty liver disease characterized by hepatocyte inflammation that contributes to fibrosis, cirrhosis, and liver failure. NASH is closely linked to obesity and diabetes; changes in diet have thus contributed to its expansion and impact across the globe. Understanding the underlying biology of fibrosis is critical for the diagnosis, treatment, and management of cardiac fibrosis, NASH, and other fibrotic diseases.
During the webinar, viewers will:
- Hear about how fibrosis can contribute to diseases of the heart and liver
- Learn more about the underlying biological mechanisms and signaling pathways involved in fibrosis and inflammation
- Gain an understanding of the biological drivers specific to nonalcoholic steatohepatitis (NASH) and cardiac fibrosis
- Have an opportunity to put their questions to the panel during the live broadcast.
This webinar will last for approximately 60 minutes.